Full-Time

Quality Assurance Auditor

Posted on 8/18/2026

Deadline 7/14/27
hVIVO

hVIVO

201-500 employees

End-to-end viral challenge trials for vaccines

No salary listed

London, UK

Hybrid

Site-based approximately three days per week.

Bachelor's

Category
QA & Testing (1)
Required Skills
Quality Assurance (QA)

Get referred to hVIVO

See people who can refer or advise you

Requirements
  • Demonstrated experience in quality assurance auditing and quality system experience.
  • Excellent knowledge of Good Clinical Practice and Good Clinical Practice for laboratories regulatory standards.
  • Experience with Good Clinical Practice or Good Clinical Practice for laboratories in pharmaceutical, contract research organization, National Health Service, or academic settings.
  • Proven knowledge of drug development processes.
  • Working knowledge of Good Laboratory Practice and Good Manufacturing Practice standards.
  • Ability to communicate with all levels within hVIVO.
  • A pragmatic and diplomatic approach to problem solving.
  • Excellent attention to detail.
Responsibilities
  • Plan and conduct assigned audits of hVIVO processes, systems, facilities, studies, and documents, including protocols, reports, and computer system validation documents, in line with the annual audit programme and appropriate study audit plans.
  • Plan and conduct assigned remote audits of low- to medium-risk suppliers and subcontractors.
  • Plan, conduct, and follow up on audits of high-risk suppliers at supplier on-site premises.
  • Follow up and close out assigned audits, including agreeing on the appropriateness of corrective actions to audit findings with relevant hVIVO staff.
  • Assess compliance with the hVIVO Quality Management System and ensure appropriate actions are agreed and followed up effectively.
  • Maintain up-to-date knowledge of current regulations, guidelines, and hVIVO standard operating procedures.
  • Review previous audit reports and relevant legislation and guidance when planning audits.
  • Produce audit plans detailing the scope of audits where relevant.
  • Conduct allocated process, system, facility, study, document, and data audits by reviewing documentation, observing procedures, and conducting tours.
  • Assess compliance and categorize audit findings appropriately.
  • Conduct audit close-out meetings to present findings to relevant hVIVO staff.
  • Produce audit reports detailing audit summaries, scopes, and findings and present them for peer review.
  • Conduct peer reviews of colleagues' audit reports for accuracy and appropriateness of findings and classifications.
  • Follow up on audit responses that are not received within assigned timeframes.
  • Assess audit responses for the appropriateness of corrective and preventive actions and advise auditees on appropriate responses until agreement is reached.
  • Conduct Quality Assurance reviews of standard operating procedures and associated Master Forms as part of the review and approval system within QuMas.
  • Plan, conduct, and follow up on audits across all hVIVO business areas, audit types, and document types, including laboratories, clinical operations, data management, and computer system validation.
  • Plan, conduct, and follow up on allocated remote questionnaire and due-diligence audits of suppliers and subcontractors.
  • Compile relevant questions to assess compliance of services being provided.
  • Assess supplier or subcontractor information to determine suitability to provide services to hVIVO and add approved providers to the Quality Assurance approved suppliers list.
  • Plan, conduct, and follow up on-site supplier audits in line with the supplier audit plan.
  • Act as Lead Auditor for on-site audits of suppliers and subcontractors.
  • Liaise with relevant hVIVO staff to determine the required audit scope for suppliers and subcontractors.
  • Assist with external sponsor audits and regulatory inspections.
  • Manage the back room for sponsor and regulatory audits.
  • Liaise with relevant hVIVO staff to provide documents requested during audits and inspections.
  • Assist with compiling responses to audit reports from sponsors and regulatory authorities.
  • Attend external training courses when required and provide feedback to Quality Assurance.
  • Maintain membership in the Research Quality Association and stay current with industry practices, regulatory requirements, and industry news.
Desired Qualifications
  • A degree in Science or equivalent.

hVIVO provides end-to-end clinical trial services centered on human viral challenge studies, mainly for infectious and respiratory diseases. Its work includes designing and conducting controlled human infection trials to test vaccines and antiviral drugs, with access to healthy volunteers through its recruitment arm, FluCamp. Trials may involve challenge agents to evaluate preventive and therapeutic candidates, and the company also explores treatments for other diseases such as malaria. Revenue comes from service contracts and research collaborations with pharmaceutical companies, biotech firms, and research institutions, making it easier to move vaccines and therapies from concept to clinical assessment while advancing global health research.

Company Size

201-500

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1989

Get referred to hVIVO

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Orderbook doubled to £65m by 30 June 2026, improving visibility through 2028.
  • April 2026 Traws and June 2026 Decoy deals expand respiratory antiviral demand.
  • October 2025 hMPV, RSV B, and Omicron models broaden the commercial challenge-library.

What critics are saying

  • Traws’ June 2026 MHRA negative review shows challenge-study approvals can block revenue.
  • H1 2026 revenue fell to £16.3m; timing slips already pushed contracts into 2027.
  • Cash was £13m on 30 June 2026; execution delays can force dilution.

What makes hVIVO unique

  • hVIVO runs the world’s largest human challenge quarantine facility in London.
  • It delivered 2,477 viral challenge trials and inoculated over 5,000 participants.
  • Its four-service platform spans consulting, trials, challenge models, and laboratories across UK, Germany.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Pharmaceutical Technology
Jun 2nd, 2026
Decoy Therapeutics partners with hVIVO to advance lead D-MAV(TM) candidate into the clinic.

Decoy Therapeutics partners with hVIVO to advance lead D-MAV(TM) candidate into the clinic. 2 June 2026 Decoy Therapeutics Inc., a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies. Decoy has engaged hVIVO, a purpose-built, full-service international clinical development partner and global leader in human challenge studies, to support translational modeling, regulatory strategy, clinical development planning, and Phase 1 and Phase 2a human proof-of-concept study preparation for Decoy's lead D-MAV candidate. The outputs will serve as a future rapid preclinical and clinical template for Decoy's growing portfolio of D-MAV drug candidates. Decoy believes its platform architecture may allow for similar clinical trial designs across multiple D-MAV candidates, subject to regulatory feedback. The initiative brings together Decoy's proprietary IMP[3]ACT(TM) platform for D-MAV discovery, which uses AI-enabled peptide design running on Google Cloud, with the translational, regulatory, clinical development and infectious disease drug development expertise and substantial capabilities of hVIVO. The collaboration is intended to support the clinical advancement of Decoy's lead respiratory antiviral candidates, which are designed to target shared viral mechanisms across multiple respiratory viruses using a single adaptable therapeutic approach. "Traditional antiviral development has largely followed a one-drug, one-virus model," said Barbara Hibner, Founder and Chief Scientific Officer of Decoy Therapeutics. "Our IMP[3]ACT platform was built to move faster than that. By combining AI-enabled design with rapid synthesis, we are working to take a D-MAV candidate from concept toward the clinic on a timeline that keeps pace with how viruses actually evolve." Under the agreement, hVIVO will support Decoy across translational modeling, regulatory strategy, scientific advice preparation, Chemistry Manufacturing and Controls (CMC) consulting, non-clinical development support, and preparation of key clinical and regulatory documentation required for European and UK clinical trial submissions. The engagement includes support for regulatory interactions with both the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). Decoy intends to conduct early proof-of-concept and likely follow-on studies with hVIVO, given its track record in human challenge trials. Decoy also plans to pursue US registration of its D-MAVs with the FDA. Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said "The antiviral landscape continues to evolve as sponsors seek new approaches to address respiratory viruses and strengthen pandemic preparedness. Decoy's programmes represent a differentiated approach, and we are pleased to be supporting the company as it progresses towards the clinic. This collaboration highlights the growing demand for integrated development partners that can support biotechnology companies from early development strategy through to clinical execution." In parallel, Decoy intends to utilize outputs generated through hVIVO's consultancy program to inform clinical development strategy, first-in-human dose selection, translational pharmacology planning, challenge study design considerations, and Phase 2a human proof-of-concept readiness activities. The combined effort is designed to support Decoy's transition into the clinic by aligning translational science, regulatory planning, and early clinical execution around a unified development pathway. "Viral disease shouldn't require a new drug for every new threat, and it shouldn't take years to reach the people who need it most," said Rick Pierce, Chief Executive Officer, Decoy Therapeutics. "We're building D-MAVs as a new category of antiviral, one designed to work across multiple viruses and built from the start for the markets, governments, and global health partners who can get them to patients at scale. Our partnership with hVIVO is a critical step toward proving that approach in human studies." Decoy's lead programs are focused on respiratory viral infections and are designed to support broader preparedness strategies against evolving and emerging viral threats. The company believes its platform architecture may enable more rapid optimization and adaptation compared to traditional antiviral development approaches. The company expects the collaboration activities to support filing IND/CTAs, translational package development, regulatory engagement preparation, and the design of future phase 1 and human proof-of-concept studies. About Decoy Therapeutics Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP[3]ACT platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment. The company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease. Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "can," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT(TM) platform. Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Decoy's actual results may vary materially from those expected or projected. About hVIVO hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies. The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first-in-human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany. With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories. * Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation. * Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database. * Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure. * Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

Novus Communications Limited
May 13th, 2026
hVIVO #HVO - Result of AGM.

hVIVO #HVO - Result of AGM. London, UK - 13 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that all resolutions put to shareholders at the Company's Annual General Meeting ('AGM') held earlier today were duly passed. The voting results of the AGM will be published on the Company website shortly: https://hvivo.com/company-documents/ For further information please contact: | hVIVO plc | +44 (0)20 7756 1300 | | Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer | / | | Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7220 0500 | | Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales | / | | Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 | | James Steel, Dr Christopher Golden | / | | Davy (Joint Broker) | +353 (0) 1 679 6363 | | Anthony Farrell, Niall Gilchrist | / | | ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson | [email protected] |

Yahoo Finance
Apr 20th, 2026
3 UK penny stocks with over $76M market cap show promise

Optima Health, a UK-based occupational health and wellbeing services provider, serves both public and private sectors with a market capitalisation of £167.79 million. The company operates in a market experiencing fluctuations due to global economic factors, including weak Chinese trade data affecting the FTSE 100 index. Optima Health has received a four-star financial health rating from Simply Wall St. The firm is amongst 276 UK penny stocks identified in a recent screening, representing potential growth opportunities in smaller companies with solid fundamentals. These stocks, whilst carrying higher volatility, can offer promising prospects for investors seeking exposure beyond established market giants.

UK Investor Magazine
Apr 14th, 2026
hVIVO lands influenza challenge trial contract with Traws Pharma.

hVIVO lands influenza challenge trial contract with Traws Pharma. 14/04/2026 hVIVO (AIM: HVO) has signed a clinical trial agreement with Nasdaq-listed Traws Pharma to conduct a human challenge trial testing a novel influenza antiviral, in a deal that underscores continued commercial momentum for the Canary Wharf-based specialist. TXM is an investigational oral, single-dose antiviral being developed to treat seasonal influenza and bird flu. The randomised, double-blinded, placebo-controlled trial will assess the drug's safety, tolerability and effectiveness in reducing the incidence and severity of influenza in healthy adults. The study will take place at hVIVO's specialist quarantine facilities in Canary Wharf, with approximately 150 participants recruited through the company's FluCamp arm. All associated laboratory work will be conducted by hVIVO's in-house virology laboratory. The trial is expected to commence in the first half of 2026, with the majority of revenue recognised this year. Iain D. Dukes, Chief Executive Officer of Traws Pharma, said: "This agreement represents an important step forward for Traws as we advance our programme and seek to generate high-quality, efficacy clinical data efficiently. Partnering with hVIVO enables us to leverage a proven human challenge platform to support our development strategy and accelerate progress towards our next value-inflection point." Seasonal influenza is responsible for an estimated one billion cases annually, with 3-5 million severe cases and up to 650,000 deaths worldwide each year. - Advertisement - hVIVO has inoculated more than 5,000 participants across 2,477 influenza, RSV and other viral human challenge trials to date. The company also announced a corporate rebranding on Tuesday, which will see all operating companies trade under the hVivo brand.

Novus Communications Limited
Nov 27th, 2025
#HVO hVIVO PLC - MSD to acquire Cidara

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates its client Cidara Therapeutics, Inc ("Cidara" or the "partner") which has entered into a definitive agreement under which Merck Sharp & Dohme LLC ("MSD"), through a subsidiary, will acquire Cidara for a total transaction value of approximately $9.2 billion. This transaction underscores the value of hVIVO's unique capabilities in accelerating drug development and validates the Company's strategic role in supporting breakthrough therapies. Cidara's lead candidate, CD388 is an investigational, long-acting, strain-agnostic antiviral agent designed to prevent influenza infection in individuals at higher risk of complications and offers protection against both influenza A and B. CD388 is currently in Phase III clinical development and has received Breakthrough Therapy Designation and Fast Track Designation from the U.S. FDA. hVIVO has partnered with Cidara throughout the development of CD388, delivering critical data that enabled its progression from early proof-of-concept to late-stage trials. Completed in 2023, hVIVO conducted a randomized, double-blind influenza human challenge study in healthy volunteers, providing early proof-of-concept data for CD388 ahead of later stage trials. 59 study participants were enrolled into the study and the primary efficacy analysis comparing the total viral load (area under the curve / AUC) showed a reduction in the CD388 treated arm compared to placebo. Similarly, the peak viral loads measured by both qPCR and cell culture were lowered in CD388 treated participants compared to placebo. Building on this success hVIVO continued to support the development of CD388, participating as the only UK site in Cidara's Phase IIb field study conducted over the 2024 / 2025 flu season assessing the protective efficacy of CD388 in healthy adults. During the study, hVIVO delivered its largest-ever number of participants enrolled into a field trial, screening more than 1,100 participants and dosing 817 within six weeks, achieving the highest recruiting numbers of all sites across the globe. This achievement demonstrated hVIVO's ability to execute large-scale field studies with speed and precision. The Phase IIb data read-out showed that all the primary and secondary endpoints were met. The Company continues to support Cidara through Phase III development, acting as a major clinical site for the ongoing multi-site trial. In addition, hVIVO has acted as the central Virology Laboratory for both of Cidara's CD388 Phase IIb and Phase III programs. As part of this service provision hVIVO has provided scientific consultancy, assembled sample collection kits, managed global virology sample logistics, and is responsible for multiple virology and immunology assays including the primary endpoint analysis. Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "We congratulate Cidara on this landmark transaction in the infectious disease space with MSD. For hVIVO, this demonstrates that our human challenge trial expertise can indeed lead to significant downstream value creation. It also validates hVIVO's diversification into field studies and standalone laboratory services, facilitated by our highly efficient patient recruitment and site services along with our extensive infectious disease knowledge and capabilities. We are proud to have supported CD388 from early proof-of-concept through Phase IIb and into Phase III, and we look forward to patients benefitting from this innovative therapy." | hVIVO plc | +44 (0)20 7756 1300 | | Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer | / | | Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) | +44 (0)20 7220 0500 | | Geoff Nash, Callum Davidson, Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales | / | | Peel Hunt LLP (Joint Broker) | +44 (0)20 7418 8900 | | James Steel, Dr Christopher Golden | / | | Davy (Joint Broker) | +353 (0) 1 679 6363 | | Anthony Farrell, Niall Gilchrist | / | | Walbrook PR (Financial PR & IR) Paul McManus / Alice Woodings / Lianne Applegarth | +44 (0)20 7933 8780 or [email protected] +44 (0)7980 541 893 / +44 (0)7407 804 654/ +44 (0)7584 391 303 | | / | / | / | / | / |